Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.
Enas M KamalMortada El-ShabrawiHisham El-KhayatNaglaa M. KamalYehia SamehYasser FouadDina AttiaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
Sofosbuvir/ledipasvir combination is safe and tolerable in the chronic infected HCV genotype 4 infected children (3-6 years). The 8-week treatment duration is similarly effective as the 12-week duration.